128 related articles for article (PubMed ID: 12859618)
21. Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.
Bargiotti A; Casazza AM; Cassinelli G; Di Marco A; Penco S; Pratesi G; Supino R; Zaccara A; Zunino F; Arcamone F
Cancer Chemother Pharmacol; 1983; 10(2):84-9. PubMed ID: 6831630
[TBL] [Abstract][Full Text] [Related]
22. Acetaminophen stimulates the peroxidative metabolism of anthracyclines.
Reszka KJ; Britigan LH; Rasmussen GT; Wagner BA; Burns CP; Britigan BE
Arch Biochem Biophys; 2004 Jul; 427(1):16-29. PubMed ID: 15178484
[TBL] [Abstract][Full Text] [Related]
23. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
Paul C; Peterson C; Gahrton G; Lockner D
Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
[TBL] [Abstract][Full Text] [Related]
24. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
Ferraro C; Quemeneur L; Prigent AF; Taverne C; Revillard JP; Bonnefoy-Berard N
Cancer Res; 2000 Apr; 60(7):1901-7. PubMed ID: 10766178
[TBL] [Abstract][Full Text] [Related]
25. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
26. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.
Supino R; Prosperi E; Formelli F; Mariani M; Parmiani G
Br J Cancer; 1986 Jul; 54(1):33-42. PubMed ID: 3730255
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
Krishan A; Sridhar KS; Mou C; Stein WD; Lyubimov E; Hu YP; Fernandez H
Clin Cancer Res; 2000 Apr; 6(4):1508-17. PubMed ID: 10778983
[TBL] [Abstract][Full Text] [Related]
29. Toxicological studies with a novel synthetic anthracycline, the bis-hydrazone bridged analog of 4-demethoxydaunorubicin (SC-33428).
Zbinden G; Beilstein AK; Bachmann E
Arzneimittelforschung; 1984; 34(10):1298-301. PubMed ID: 6542790
[TBL] [Abstract][Full Text] [Related]
30. Peroxidase- and nitrite-dependent metabolism of the anthracycline anticancer agents daunorubicin and doxorubicin.
Reszka KJ; McCormick ML; Britigan BE
Biochemistry; 2001 Dec; 40(50):15349-61. PubMed ID: 11735418
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
32. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin.
Wheeler HR; Geczy CL
Int J Cancer; 1990 Oct; 46(4):626-32. PubMed ID: 2120134
[TBL] [Abstract][Full Text] [Related]
33. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
34. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
35. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
36. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues.
Ashikawa K; Shishodia S; Fokt I; Priebe W; Aggarwal BB
Biochem Pharmacol; 2004 Jan; 67(2):353-64. PubMed ID: 14698047
[TBL] [Abstract][Full Text] [Related]
37. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-O-methyl-doxorubicin.
Zunino F; Barbieri B; Bellini O; Casazza AM; Geroni C; Giuliani F; Ciana A; Manzini G; Quadrifoglio F
Invest New Drugs; 1986; 4(1):17-23. PubMed ID: 3700037
[TBL] [Abstract][Full Text] [Related]
39. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.
Mirabelli CK; Sung CM; McCabe FL; Faucette LF; Crooke ST; Johnson RK
Cancer Res; 1988 Oct; 48(19):5447-54. PubMed ID: 3046738
[TBL] [Abstract][Full Text] [Related]
40. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.
Trouet A; Deprez-De Campeneere D
Cancer Chemother Pharmacol; 1979; 2(1):77-9. PubMed ID: 498424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
